share_log

济川药业(600566.SH):拉呋替丁片获得药品注册证书

Hubei Jumpcan Pharmaceutical (600566.SH): Lafutidine tablets obtained pharmaceutical registration certificate.

Gelonghui Finance ·  Sep 4 04:18

On September 4th, GeLonghui reported that Hubei Jumpcan Pharmaceutical (600566.SH), a wholly-owned subsidiary of Hubei Jumpcan Pharmaceutical Group Co., Ltd., has received the Drug Registration Certificate for Lafutidine issued by the National Medical Products Administration. Lafutidine is a new type of histamine H2 receptor antagonist that inhibits gastric acid secretion and enhances mucosal protective factors.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment